reports
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Wim Hoste
Ontex Model update post profit warning
Ontex issued a severe profit warning which implies the company now expects 4Q25 adjusted EBITDA to land at € 38-43m vs a previous expectation range of € 63-68m, with the downwards revision due to intense competition from A-brands in the baby care segment. We have reduced our adjusted EBITDA forecasts for FY25-27 by between 8-10%, but still expect FY26 EBITDA to grow by c. 12% vs our new FY25 forecast, on a combination of efficiency measures, the full contribution of new contracts and (at some po...
- Jacob Mekhael
argenx Vyvgart phase 3 in TED stopped due to lack of efficacy
argenx announced that the phase 3 (UplighTED) studies evaluating Vyvgart subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED) will be discontinued following a pre-specified unblinded interim analysis from patients completing 24 weeks of treatment. The decision to stop the trial due to lack of efficacy in TED is disappointing, however, the company notes that its pipeline strategy anticipates attrition. Of the 2026 phase 3 readouts, TED was the only program where argenx le...
- Thomas Couvreur
ABN Amro NIBC, Wealth & Staff reductions drive value; target price inc...
We have reviewed our model on ABN Amro, incorporating the NIBC acquisition, the ambitious growth targets in Wealth Management and the aggressive cost savings targets, mainly driven by FTE reductions. By FY28 we see our income estimates increase by 4.3% and cost estimates decrease by 3.1%. Our new SoTP valuation points to a target price of €29 (vs €25.5), reiterating our Hold recommendation given limited upside.
- Wim Lewi
Care Property Invest Upgrade to Accumulate after rights issue and majo...
We like the pro-active nature of this deal. CPI completed a capital increase of €55.5m to finance the acquisition of 9 healthcare assets for €142.6m (announced on 3/12). The remaining €87.1m was financed by €47.1m new debt and €40m of existing debt at a low rate (2.9%). This deal will offset the overhang of the lease portfolio expiries for the next 10 years. Hence, CPI addresses a concern that has been weighing on the share price. The rights issue take-up amounted to 62.6%. We believe this is a ...
La protonthérapie, nouvelle norme de soins pour les patients atteints ...
La protonthérapie, nouvelle norme de soins pour les patients atteints d'un cancer de l'oropharynx Louvain-la-Neuve, Belgique, le 15 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, a le plaisir d'annoncer aujourd'hui que The Lancet – l'une des revues scientifiques les plus renommées au monde – a publié, le 11 décembre, une étude historique recommandant la protonthérapie comme nouvelle norme de soins pour les patients atteints d'...
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyr...
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Monitoring ...
Proton Therapy New Standard of Care for Patients with Oropharyngeal Ca...
Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer Louvain-La-Neuve, Belgium, December 15, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11, The Lancet – one of the world’s most renowned academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. , led by MD Anderson Cancer Center, the world’s ...
Exor Press Release - Announcement on Juventus
Exor Press Release - Announcement on Juventus Amsterdam, 13 December 2025 EXOR BOARD UNANIMOUSLY REJECTS TETHER’S PROPOSAL TO ACQUIRE EXOR’S CONTROLLING STAKE IN JUVENTUS Exor N.V. (“Exor” or the “Company”) announces that its Board of Directors has unanimously rejected an unsolicited proposal submitted by Tether Investments, S.A. de C.V. (“Tether”) to acquire all of the shares of Juventus Football Club S.p.A. (“Juventus” or the “Club”) owned by Exor. Exor reaffirms its previous, consistent statements that it has no intention of selling any of its shares in Juventus to a third party, incl...
- Carole Braudeau
- Carole Braudeau
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
- Tanvi Arora
- Carole Braudeau
- Carole Braudeau
- Aurelien Sivignon
- Yan Derocles
- ING Helpdesk
Benelux Morning Notes
Belgian Telecoms: DIGI Belgium CEO Interview: ‘We are running a marathon, not a sprint' IBA: IBA to install a Rhodotron in East China. Ontex: Another quarter, another profit warning. Theon International: Backlog visibility indeed. Xior: 2026 outlook positive but with no major surprise. Events Calendar
- Aurelien Sivignon
- Yan Derocles
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.